Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165112 · ClinicalTrials.gov registry record · Phase 1
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
A Phase 1 study of Recurrent Adult Diffuse Large Cell Lymphoma and Recurrent Adult Hodgkin Lymphoma, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01165112 is a Phase 1 study of Recurrent Adult Diffuse Large Cell Lymphoma and Recurrent Adult Hodgkin Lymphoma that has completed, run by University of Washington. The registered enrollment target is 48 participants, above the 38-participant average among 10 other Recurrent Adult Diffuse Large Cell Lymphoma trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01165112, a Phase 1 study of Recurrent Adult Diffuse Large Cell Lymphoma and Recurrent Adult Hodgkin Lymphoma, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with carboplatin, etoposide, and rituximab in treating patients with diffuse large B cell lymphoma or Hodgkin lymphoma that has come back after a period of improvement or has not responded to previous treatment. Drugs used in chemotherapy, such as bendamustine hydrochloride, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, may block cancer growth by targeting certain cells. Giving bendamustine hydrochloride together with carboplatin, etoposide, and rituximab may kill more cancer cells.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Etoposide
- BIOLOGICAL Rituximab
- DRUG Bendamustine Hydrochloride
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165112
The ClinicalTrials.gov registry entry for NCT01165112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 10 other Recurrent Adult Diffuse Large Cell Lymphoma trials with a reported enrollment target (26% higher). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Adult Diffuse Large Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT01165112 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01165112 about?
NCT01165112 is a clinical study titled "Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma". This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with carboplatin, etoposide, and rituximab in treating patients with diffuse large B cell lymphoma or Hodgkin lymphoma that has come back after a period of improvement or has not respon...
What is the current status of trial NCT01165112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2010-09. Estimated completion is 2015-06.
What conditions does trial NCT01165112 study?
This clinical trial studies the following conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma.
What interventions are being tested in trial NCT01165112?
The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Etoposide (DRUG), Rituximab (BIOLOGICAL), Bendamustine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01165112?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01165112 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Diffuse Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
COMPLETED · Phase 1
-
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
-
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
-
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Adult Diffuse Large Cell Lymphoma
All registered trials for this condition
Recurrent Adult Hodgkin Lymphoma
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.